2025
Self-affirmation intervention for patients newly diagnosed with advanced cancer: a preliminary efficacy trial
Bai M, Cella D, Jeon S, Govindarajan R, Birrer M. Self-affirmation intervention for patients newly diagnosed with advanced cancer: a preliminary efficacy trial. Journal Of Psychosocial Oncology 2025, ahead-of-print: 1-23. PMID: 39812781, DOI: 10.1080/07347332.2025.2450013.Peer-Reviewed Original ResearchFunctional Assessment of Cancer Therapy - GeneralAdvanced cancerCancer patients' quality of lifeFACIT-Sp-12Functional assessmentInterrupted time series designPost-intervention changesCancer patients' qualityTime series designQuality of lifePatients' quality of lifePost-interventionPsychosocial interventionsAdvanced stage cancerLinear mixed modelsGeneralized linear mixed modelsSeries designPreliminary efficacyCancer diagnosisIntent-to-treat analysisSelf-affirmation interventionChanges pre-Existential concernsIntervention approachesItem scale
2024
Navigating life after New-onset refractory status epilepticus (NORSE) and Febrile infection-related epilepsy syndrome (FIRES): Insights from caregiver and patient interviews
Eschbach K, Reedy J, Gofton T, Gopaul M, Farias-Moeller R, Kellogg M, Knupp K, Hirsch L, Wong N, Dorsey Holliman B. Navigating life after New-onset refractory status epilepticus (NORSE) and Febrile infection-related epilepsy syndrome (FIRES): Insights from caregiver and patient interviews. Epilepsy & Behavior 2024, 163: 110236. PMID: 39740258, DOI: 10.1016/j.yebeh.2024.110236.Peer-Reviewed Original ResearchConceptsQuality of lifeCaregivers' quality of lifeDyadic semi-structured interviewsEmotional quality of lifeThematic content analysis approachComorbid health concernsHealth concernBehavioral health concernsContent analysis approachSignificant life changesMedication side effectsSemi-structured interviewsPatients' quality of lifeRisk of mortalityLife-altering impactPatient interviewsPatient independenceCaregiversNeurologically healthy individualsLife changesNew-onset refractory status epilepticusImpact patients' quality of lifeFebrile infection-related epilepsy syndromeFamily membersLong-term impactComparing the Accuracy and Reliability of ABC/2 and Planimetry for Vestibular Schwannoma Volume Assessment
Singh K, Abdou H, Panth N, Chiang V, Buono F, Schwartz N, Mahajan A. Comparing the Accuracy and Reliability of ABC/2 and Planimetry for Vestibular Schwannoma Volume Assessment. Otology & Neurotology 2024, 46: 196-200. PMID: 39792983, DOI: 10.1097/mao.0000000000004392.Peer-Reviewed Original ResearchConceptsTumor volume assessmentABC/2 methodVestibular schwannomaVolume assessmentPlanimetry methodTumor volumeTumor volume changesFollow-up scansOverestimate tumor volumePatients' quality of lifeTumor sizeRetrospective reviewIntracranial tumorsImprove clinical decision makingSubgroup analysisVolumetric assessmentTumorClinical decision makingQuality of lifePatients' qualityPatientsClinical settingPlanimetryImaging techniquesPositive correlationThe 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile
Boustany A, Feuerstadt P, Tillotson G. The 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile. Advances In Therapy 2024, 41: 3982-3995. PMID: 39276186, PMCID: PMC11480130, DOI: 10.1007/s12325-024-02972-0.Peer-Reviewed Original ResearchIncreased risk of C. difficile infectionRisk of C. difficile infectionClasses of antidepressantsClostridioides difficile infectionNovel treatment optionsPatients' quality of lifeMicrobiome-related factorsDevelopment of dysbiosisOpportunistic infectionsRecurrent CDIGut microbiomeRecurrence rateAntidepressant useDifficile infectionMental disordersTreatment optionsLive biotherapeutic productsComplex pathophysiologyIncreased riskC. difficileGut dysbiosisQuality of lifePatients' qualitySignificant healthcare concernAntidepressantsUsing Neuromodulators for Salivary, Eccrine, and Apocrine Gland Disorders
Rajanala S, Salame N, Dover J. Using Neuromodulators for Salivary, Eccrine, and Apocrine Gland Disorders. Dermatologic Surgery 2024, 50: s103-s111. PMID: 39196843, DOI: 10.1097/dss.0000000000004262.Peer-Reviewed Original ResearchConceptsQuality of lifeParasympathetic cholinergic neuronsBotulinum toxinLong-term treatmentPatients' quality of lifeTreatment of sialorrheaBotulinum toxin serotype ABotulinum toxin treatmentToxin serotype AImpact patient healthStandard doseGlandular disordersOff-labelOnabotulinumtoxin AIncobotulinumtoxin AAxillary hyperhidrosisNoninvasive treatmentPatient healthApplication of neuromodulationCholinergic neuronsPatients' qualityApocrine glandsHyperhidrosisSerotype BToxin treatmentPredicting peripheral neuropathy following neoadjuvant therapy in patients with breast cancer.
Feiger B, Biancalana M, Shelton A, Blenman K, Lustberg M. Predicting peripheral neuropathy following neoadjuvant therapy in patients with breast cancer. Journal Of Clinical Oncology 2024, 42: e12639-e12639. DOI: 10.1200/jco.2024.42.16_suppl.e12639.Peer-Reviewed Original ResearchBreast cancer patientsNeoadjuvant chemotherapyPeripheral neuropathyNeoadjuvant therapyBreast cancerCancer patientsAdministration of neoadjuvant chemotherapyCohort of breast cancer patientsLikelihood of breast-conserving surgeryContrast-enhanced magnetic resonance imagingQuality of lifeDynamic contrast-enhanced magnetic resonance imagingBreast-conserving surgeryReduced tumor burdenTreatment-induced neuropathyOccurrence of neuropathyInduce peripheral neuropathyDensity of blood vesselsPatients' quality of lifeMagnetic resonance imagingAmeliorate neuropathyDCE-MRI dataTumor burdenCumulative toxic effectsIntratumoral vascularityEnhanced Recovery After Surgery Cardiac Society turnkey order set for surgical-site infection prevention: Proceedings from the American Association for Thoracic Surgery ERAS Conclave 2023
Crisafi C, Grant M, Rea A, Morton-Bailey V, Gregory A, Arora R, Chatterjee S, Lother S, Cangut B, Engelman D, Group E, Salenger R, Lobdell K, McConnell G, Crotwell S, Reddy S, Lazar H. Enhanced Recovery After Surgery Cardiac Society turnkey order set for surgical-site infection prevention: Proceedings from the American Association for Thoracic Surgery ERAS Conclave 2023. Journal Of Thoracic And Cardiovascular Surgery 2024, 168: 1500-1509. PMID: 38574802, DOI: 10.1016/j.jtcvs.2024.03.027.Peer-Reviewed Original ResearchSurgical site infectionCardiac surgeryManagement of surgical site infectionsHigher risk of surgical site infectionImplementation of evidence-based best practicesCardiac surgery increases morbidityRisk of surgical site infectionClass IConsume healthcare resourcesCardiac surgical populationSurgical site infection reductionEvidence-based best practicesProphylactic intravenous antibioticsManaging surgical site infectionsMultidisciplinary care pathwaySurgical site infection preventionPatients' quality of lifeExpert consensus documentQuality of lifeNasal carriageIntravenous antibioticsBlood glucose levelsPatient engagementSSI riskPreoperative identificationPatient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab
Milowsky M, O'Donnell P, Hoimes C, Petrylak D, Flaig T, Moon H, Friedlander T, Mar N, McKay R, Srinivas S, Gravis G, Ramamurthy C, Bupathi M, Bracarda S, Wright P, Hepp Z, Carret A, Yu Y, Dillon R, Kataria R, Beaumont J, Purnajo I, Rosenberg J. Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. Journal Of Clinical Oncology 2024, 42: 1403-1414. PMID: 38215355, PMCID: PMC11095879, DOI: 10.1200/jco.23.01547.Peer-Reviewed Original ResearchBPI-SF worst painPatient-reported outcomesEnfortumab vedotinEORTC QLQ-C30 quality of lifeBPI-SFQuality of lifeCisplatin-ineligibleUrothelial cancerWorst painTreatment armsBrief Pain Inventory Short FormAdvanced urothelial cancerPhase Ib/II trialBaseline to weekPatient-reported outcomes analysisAssociated with preservationTreatment of Cancer Quality of Life Questionnaire-Core QuestionnairePatients' quality of lifeSmall-to-moderate improvementsClinically meaningful improvementsPatient-reported outcome instrumentsEuropean Organization for Research and TreatmentEORTC QLQ-C30First-lineClinical outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply